Document is current
Any future updates will be listed below
-
Authors
Dadson, Prince
Ylä-Outinen, Heli
Kalliokoski, Kari
Tuokkola, Terhi
Malaspina, Simona
Koivumäki, Mikko
Viitanen, Riikka
Rajala, Noora
Silvoniemi, Maria
Tolvanen, Tuula
Nuutila, Pirjo
Jalkanen, Sirpa
Saraste, Antti
Saaresranta, Tarja
Taimen, Pekka
Roivainen, Anne
-
Funding
Funding for this research was provided by:
Jane ja Aatos Erkon Säätiö
Research Council of Finland (350117)
Turun Yliopistollinen Keskussairaala (13856)
- License Information
-
More Information
Article History
Received: 28 June 2025
Accepted: 12 December 2025
First Online: 19 December 2025
Declarations
:
: The study was approved by the joint Ethics Committee of the University of Turku and Turku University Hospital (ETMK 35/1800/2018), and by the Finnish Medicines Agency (EudraCT 2018-001002-29). Each subject provided informed consent before entering the study. The study was registered as a clinical trial (NCT03755245). A lung cancer patient participated in another clinical trial NCT05212103 (ETMK 101/2021), but dropped out after the first scan.
: Not applicable.
: Maria Silvoniemi received speaker fees and/or honoraria for advisory boards from MSD, BMS, Roche, Pfizer, AstraZeneca, Amgen, Novartis, and Boehringer-Ingelheim (not related to the current study). Antti Saraste has consultancy fees from AstraZeneca, Novo Nordisk, and Pfizer, and speaker fees from Abbott, AstraZeneca, BMS, Janssen, and Pfizer (not related to the current study). Sirpa Jalkanen owns patent regarding VAP-1 as a target for imaging. The remaining authors have no conflicts of interest to disclose.
